Millennium Increasing Integrilin Sales Force, Emphasizing Earlier Use
Executive Summary
Millennium is increasing the size of its Integrilin sales force and encouraging earlier use of the glycoprotein IIb/IIIa inhibitor
You may also be interested in...
Millennium Retains Velcade U.S. Rights; J&J Picks Up Half Of R&D Costs
Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials